When you have a program that has stalled or gone off schedule, it is vital to team up with a CRO laboratory that is capable of handling quick turnarounds and rescue projects. We look at an example of how BioAgilytix sprung to action to transform a troubled study.
On May 7, we’ll be hosting webinar highlighting the importance of streamlining the time & cost of bioanalytical testing to support therapeutic development for viral infections such as COVID19 and influenza. We share a sneak peek of the content here.
Today we continue our celebration of Women’s History Month by highlighting another BioAgilytix team member – this time from the technology side of our business. Whitney Gonzales, IT Support Specialist, shares some of her own stories and advice about pursuing a career in STEM.
As part of Women’s History Month we’d like to highlight a few of the many inspiring women on the BioAgilytix team. First we’ve asked Dr. Jennifer Zemo to share some of her stories & advice about pursuing a career in STEM.
It’s a common misconception that all aspects of cell & gene therapy research and development are excluded from CLIA oversight. We take a closer look at testing and when CLIA requirements apply.
All CRO laboratories are not created equal. If you are looking for outsourced support for a large molecule program, consider these questions.
BioAgilytix’s Todd Lester answers additional questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.
BioAgilytix’s Todd Lester answers questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.
A new clinical trial by St. Jude Children’s Research Hospital for the treatment of SCID-X1 highlights a major advancement in gene therapy safety over recent years, in this case spurred by scientists who were courageous enough to push forward the development of safer vectors to overcome serious adverse events (SAEs) that were resulting from the previous generation of gene therapies developed for SCID-X1.
We discuss the need to put phase-appropriate methods in place to identify and quantify both process- and host-cell related impurities throughout the drug development process.